Understanding brain health in ICU patients with kidney injury
Identifying Neurocognitive Outcomes and Cerebral Oxygenation in Critically Ill Adults on Acute Kidney Replacement Therapy in the Intensive Care Unit
This study looks at how kidney injury affects brain health in critically ill adults in the ICU to see if measuring brain oxygen levels can help predict long-term thinking and memory problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 104 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Queen's University Academic / other |
| Locations | 1 site (Kingston, Ontario) |
| Trial ID | NCT04722939 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the neurocognitive outcomes of critically ill adults who have experienced acute kidney injury and are undergoing kidney replacement therapy. It focuses on measuring regional cerebral oxygen saturation as a potential early indicator of long-term cognitive impairment. By correlating these measurements with cognitive and functional outcomes, the study aims to shed light on the relationship between kidney therapy and brain health in ICU patients. The research is conducted at the Kingston Health Sciences Centre.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are admitted to the ICU with severe acute kidney injury requiring kidney replacement therapy.
Not a fit: Patients with pre-existing neurological disorders or contraindications to cerebral oximetry testing may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and interventions for cognitive impairment in ICU patients with acute kidney injury.
How similar studies have performed: While this study explores a specific aspect of cognitive outcomes in ICU patients, similar studies have indicated a link between kidney therapy and cognitive impairment, suggesting a potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age greater than or equal to 18 years * admitted to the Kingston Health Sciences Intensive Care Unit * diagnosis of severe AKI requiring Kidney Replacement Therapy (KRT) (defined by the presence of either a twofold increase in serum creatinine from baseline, serum creatinine level greater than or equal to 354 micromol/L with an increase of 27 micromol/L from baseline, or urine output \<6 mL/kg in the preceding 12 hours) * within 12 hours of initiation of KRT via intermittent hemodialysis (iHD) or continuous kidney replacement therapy (CKRT). Exclusion Criteria: * acquired or congenital neurological disorders * any contraindication to testing with cerebral oximetry, Kinarm, or MRI (e.g., claustrophobia, limb amputation, paresis, neuromuscular disorders, etc.) * KRT via PD * failure to consent * life expectancy less than 24 hours * clinical suspicion of renal obstruction * rapidly progressive glomerulonephritis or interstitial nephritis * prehospitalization eGFR \<30 mL/min/1.73m2.
Where this trial is running
Kingston, Ontario
- Kingston Health Sciences Centre — Kingston, Ontario, Canada (Recruiting)
Study contacts
- Study coordinator: J. Gordon Boyd, MD, PhD
- Email: gordon.boyd@kingstonhsc.ca
- Phone: 613-549-6666
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.